Health Canada has published a Handbook for health care professionals on biosimilar biologic drugs.
Who we are
Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.
Learn more about biosimilars and their benefits for patients and healthcare systems.
The use of oncology biosimilars has led to substantial annual savings in Ontario. In fiscal years 2020/21, 2021/22 and 2022/23, Ontario Health saved an estimated $53 million, $44 million, and $53 million, respectively.